Clinical trials
Recurrence clinical trials
Below are recruiting recurrence clinical trials, each written for real people, not researchers. We’re tracking 1,422 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+ - NCT07042295RecruitingPhase 2
Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT06399640RecruitingPhase 1
Eltanexor and venetoclax for blood cancers
This trial tests a combination of two oral drugs, eltanexor and venetoclax, for people with certain types of blood cancer that have come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
Memphis, TennesseeAges 18 years+ - NCT07774533RecruitingEarly Phase 1
Imaging osteosarcoma with a new PET tracer
This trial tests a new PET imaging tracer that may help see osteosarcoma tumors more clearly. It is for people whose osteosarcoma has not improved or has returned after standard treatment.
Beijing, Beijing MunicipalityAges 10–80 - NCT05723926Recruiting
Carotid implants to help prevent stroke repeat in atrial fibrillation
This trial tests whether placing a carotid implant can reduce the chance of having another stroke in people with atrial fibrillation who are already taking blood thinners. It aims to prevent stroke recurrence while you continue prescribed anticoagulation.
Rockford, IllinoisAges 18 years+ - NCT07214311RecruitingPhase 2/Phase 3
A trial of PLG0206 to prevent knee joint infection after surgery
This trial tests if a new drug called PLG0206 can stop a knee joint infection from coming back after a surgery called DAIR. DAIR cleans the infected area and keeps the artificial knee in place, and this study wants to see if adding PLG0206 helps prevent the infection from returning.
Sarasota, FloridaAges 18–80 - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Anchorage, AlaskaAges 18 years+ - NCT04903795RecruitingPhase 1
Testing a targeted immune therapy for EGFR-mutant glioblastoma
This Phase 1 trial tests BRiTE, a custom immune “match” therapy designed to attack glioblastoma cells that have a specific EGFRvIII change. It’s for adults with newly diagnosed or recurring grade 4 glioblastoma, aiming to see safety and whether the treatment can shrink or control tumors.
Durham, North CarolinaAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Aurora, ColoradoAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Fayetteville, ArkansasAges 18 years+ - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT07767461Recruiting
Preventing skin irritation from diabetes devices in kids
This study looks at whether protective patches under insulin pumps or glucose sensors can prevent skin irritation in children and teens with type 1 diabetes. It may help reduce discomfort and keep devices working well.
CopenhagenAges 2–18 - NCT06492616RecruitingPhase 3
Elacestrant vs standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Daphne, AlabamaAges 18 years+ - NCT07202247RecruitingPhase 2
Improving heart health in prostate cancer patients on hormone therapy
This study tests whether combining a time-restricted eating plan, a heart-healthy diet, and a weight-loss medication (GLP-1 receptor agonist) can help improve heart health and weight in men with prostate cancer who are receiving hormone therapy. It aims to reduce the risk of heart problems caused by hormone treatment.
Duarte, CaliforniaAges 30–79 - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Mobile, AlabamaAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT06843447RecruitingPhase 1/Phase 2
Study of Raludotatug Deruxtecan for Ovarian Cancer
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Birmingham, AlabamaAges 18 years+ - NCT07062536RecruitingPhase 2
Comparing Two Chemo Combos for Advanced Bile Duct Cancer
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
Busan, BusanAges 19–99 - NCT06186401RecruitingPhase 1
Experimental immune cell therapy for a specific type of brain cancer
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT06622005RecruitingPhase 1
Combination treatment for multiple myeloma that has returned
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
Buffalo, New YorkAges 18 years+ - NCT06040970RecruitingPhase 1/Phase 2
Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
New York, New YorkAges 18 years+ - NCT07125729Recruiting
Early cancer detection test for colorectal cancer
This trial uses two blood tests (Signatera and Haystack) to look for tiny bits of cancer DNA after surgery, to find out if the cancer comes back as early as possible. People with stage II, III, or IV colorectal cancer who have had or will have surgery to remove their tumor may join.
Goodyear, ArizonaAges 18 years+
Hear when a new Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrence?
- Yes. Clin2 currently lists 1,422 recruiting recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.